큐라클
Financials
Valuation Metrics
큐라클's Market Cap is ₩1770B. At end of 2025 it was ₩1580B. Ranked #867 of 2,405 in KR market (top 36%), #399 of 1,627 on KOSDAQ (top 25%), #97 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 42%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 177.03B KRW | KR#867/2,405 Sec#97/231 |
| Revenue | 7.1M KRW | KR#2,380/2,405 Sec#226/231 |
| Net Income | -7.59B KRW | KR—/2,405 Sec—/231 |
| Total Assets | 59.45B KRW | KR#2,106/2,405 Sec#184/231 |
| Net Assets | 46.70B KRW | KR#1,946/2,405 Sec#164/231 |
| Employees | 32 | KR#2,177/2,405 Sec#203/231 |
| Value | ||
| P/B | 3.79x | KR#2,194/2,405 Sec#186/231 |
| P/S | 24929.26x | KR#2,399/2,405 Sec#229/231 |
| FCF Yield | -7.60% | KR—/2,405 Sec—/231 |
| Profitability | ||
| ROE | -16.25% | KR#2,039/2,405 Sec#158/231 |
| ROA | -12.76% | KR#2,145/2,405 Sec#164/231 |
| Revenue Growth | -99.56% | KR#2,313/2,405 Sec#211/231 |
| Financial Health | ||
| Debt Ratio | 27.30% | KR#528/2,405 Sec#59/231 |
| Total Debt | 11.00B KRW | KR#1,579/2,405 Sec#141/231 |
| FCF | -13.45B KRW | KR#1,785/2,405 Sec#162/231 |
| Cash | 9.90B KRW | KR#1,700/2,405 Sec#145/231 |
| Current Ratio | 1.94x | KR#897/2,405 Sec#101/231 |
| Performance | ||
| 1Y Return | 46.34% | KR#184/2,405 Sec#7/231 |
| 1M Return | -21.67% | KR#1,958/2,405 Sec#191/231 |
| From 52W High | -61.49% | KR#1,724/2,405 Sec#143/231 |
| 1Y MDD | -63.12% | KR#1,622/2,405 Sec#134/231 |
| Trading | ||
| Volume | 13,488 shares | KR#1,706/2,405 Sec#166/231 |
| Trading Value | 107.7M KRW | KR#1,404/2,405 Sec#151/231 |
| Foreign Own. | 1.78% | KR#1,703/2,405 Sec#165/231 |
| Per Share | ||
| EPS | -342 KRW | KR—/2,405 Sec—/231 |
| BPS | 2,108 KRW | KR#2,056/2,405 Sec#172/231 |
Company Info
Established in 2016, this company is a specialized bio-venture focusing on research and development of therapeutics for endothelial dysfunction, specially listed on KOSDAQ in 2021. It builds an innovative new drug pipeline and conducts research and development based on its proprietary new drug development platforms, Solvadis and Eagles. In 2024, Rivasterat demonstrated vision improvement in a US Phase 2a clinical trial, while CU01 is expanding its portfolio through joint research and development and completion of domestic Phase 2b patient recruitment in 2025. Curacle, established in 2016, is headquartered in Seoul Metropolitan City, Seocho-gu.